加勒比海盗
Pfizer cuts full-year outlook due to declining sales of Covid-19-related products_我的网站
A | Rajinikanth was the centre of attention at the closing ceremony of the fifty sixth International Film Festival of India in Goa, where the iconic star was presented with a prestigious lifetime achievement award commemorating his extraordinary five-decade journey in Indian cinema. The seventy-four-year-old arrived with his family, including his wife Latha and daughters Aishwarya and Soundarya, and was welcomed by a packed auditorium that rose to its feet the moment he stepped on stage.Rajinikanth Commands The IFFI Stage With Grace And GratitudeGoa Chief Minister Pramod Sawant presented Rajinikanth with a ceremonial shawl and a gleaming memento as a tribute to his influence across generations. The moment was marked by loud applause, cameras flashing from every corner, and the unmistakable energy that only follows a figure who has shaped the cinematic imagination of millions. Rajinikanth, visibly moved, offered a heartfelt address that captured the humility which has always anchored his superstardom. View this post on Instagram A post shared by IFFI (@iffigoa) Looking back on his career, the actor remarked that the decades felt like a brief chapter because of his unending passion for performing. He expressed deep affection for the audience that has championed him from the beginning, stating that even with a hundred births he would choose to return as an actor and as Rajinikanth. He dedicated the honour to the larger film community that supported him and to the Tamil people whom he called the divine force that has sustained him through every stage of his life.He received a thunderous standing ovation from the entire hall, a reminder that his influence extends far beyond the screen. The ceremony also featured the presence of Dr L Murugan, Minister of State for Information and Broadcasting, Secretary Sanjay Jaju, and actor Ranveer Singh who joined him on stage to celebrate the milestone.A Superstar With Plenty More To OfferEven as the industry reflects on his fifty-year journey, Rajinikanth is already deep into his next slate of films. His upcoming project Jailer 2 has created ripples across the South Indian film landscape, with Nelson Dilipkumar returning to direct the follow up to the massive 2023 hit. Rajinikanth will reprise his role as Tiger Muthuvel Pandian, with Ramya Krishnan once again appearing as his partner on screen. Shivarajkumar, who made a crowd-pleasing entry in the first part, has confirmed his involvement in the sequel.The sequel is expected to expand its scale with a powerhouse ensemble. Industry chatter suggests that Nandamuri Balakrishna, Suraj Venjaramoodu, Vidya Balan and Mithun Chakraborty are being considered for pivotal roles, which hints at a multi-regional canvas designed to elevate the franchise into an even bigger spectacle. Music composer Anirudh Ravichander is reportedly in talks to return, adding further excitement among fans of the first film’s chart-topping album. View this post on Instagram A post shared by Soundarya Rajinikanth (@soundaryaarajinikant) Beyond Jailer 2, preparations continue for Rajinikanth’s next standalone feature, tentatively referred to as Thalaivar 173. The project recently witnessed a shift as Sundar C stepped away, prompting producer Kamal Haasan and his Raaj Kamal Films International team to initiate discussions with a fresh lineup of filmmakers. The collaboration between two of Tamil cinema’s biggest icons has already ignited curiosity, with the announcement of a new director expected soon.Rajinikanth was most recently seen in Vettaiyan, a film that extended his winning streak at the box office and reaffirmed his position as an audience magnet across age groups. His continued popularity, coupled with the packed calendar ahead of him, suggests that the star’s creative fire remains undimmed.For an actor who began as a bus conductor before entering films with K Balachander’s mentorship, the journey has been nothing short of mythic. The honour at IFFI serves not only as acknowledgment of past achievements but also as a celebration of an artist who continues to reinvent himself while staying true to his roots.Also Read: Virat Kohli And Anushka Sharma Play Pickleball With RCB Squad。 Shares of Pfizer are in retreat on the first day of trading after the drug company said sales of its COVID-19 vaccine and its coronavirus treatment are weaker than it had expected and cut revenue projections by $9 billion for the year. Falling sales of both clipped sales in the second quarter, but Pfizer said in August that it expected a rebound in the second half of 2023. Shares of Pfizer slipped more than 1% before the opening bell Monday and Moderna, which is heavily reliant on the competing vaccine it makes, slid nearly 5%. Pfizer said Friday that global usage of Paxlovid is trending slightly above last year, but that it's still below expectations.The fall vaccination period just began and the New York City drugmaker said that it's too soon to get a handle on vaccination rates for the year.Full-year revenue for Paxlovid and Comirnaty is expected to be approximately $12.5 billion, short $9 billion of what it had expected. Pfizer is lowering its full-year revenue expectations for Paxlovid by approximately $7 billion. That number also accounts for delayed commercialization of the product, which was pushed to January 2024 from the company's previous expectation of commercialization in the second half of this year. Pfizer is also lowering its 2023 revenue expectations for Comirnaty by approximately $2 billion due to lower-than-expected vaccination rates.Pfizer Inc. now foresees 2023 revenue in a range of $58 billion to $61 billion, down from its prior forecast for $67 billion to $70 billion. It now projects full-year adjusted earnings between $1.45 and $1.65 per share due to lower-than-anticipated revenue for COVID-19-related products and inventory write-offs.That is short of the full-year revenue of $63.61 billion and earnings of $2.77 per share that Wall Street was expecting, and far short of the company's previous projections of per-share earning between $3.25 and $3.45. JPMorgan said the company's update solves an ongoing U.S. Paxlovid inventory debate and it anticipates the company's bigger-than-expected cuts to its sales projections will help put a floor under per-share earnings expectations for next year.。
B |
Current article:http://www.qiniaohongfangfoguisenzhai.cyou/list_12kx/zay8.html
Published on:21:30:35